Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Instagram
  • Listen to CMAJ podcasts
SynopsisH

Treating HIV/AIDS and leishmaniasis coinfection in Ethiopia

Aranka Anema and Koert Ritmeijer
CMAJ May 24, 2005 172 (11) 1434-1435; DOI: https://doi.org/10.1503/cmaj.050511
Aranka Anema
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Koert Ritmeijer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Responses
  • Metrics
  • PDF
Loading
  • © 2005 CMA Media Inc. or its licensors

HIV/AIDS is currently recognized as the leading cause of adult illness and death in Ethiopia and has infected a cumulative total of 1 500 000 adults and children. Kafta Humera Woreda is an isolated area in the northwest region of the Ethiopian province of Tigray. Because of a combination of demographic and geographic factors, increased rates of both HIV transmission and visceral leishmaniasis (kala-azar) have posed serious public health challenges in the area.

Kafta Humera Woreda's position near the Eritrean and Sudanese borders means that it is a transit point for cross-border trade and traffic. An annual migration of male farm workers into the area causes the population to double from about 40 000 during the dry season to about 80 000 during the farming season. True to the model of supply and demand, the increased number of farmers is accompanied by an annual influx of commercial sex workers into the area. Therefore, both mobility and socioeconomic vulnerability are factors that contribute to increased rates of HIV transmission in the area. Moreover, the progression to AIDS is heightened by a limited access to health care.

Leishmaniasis is an opportunistic infection that is particularly troublesome for patients with HIV/AIDS in that it, too, attacks the immune system and thereby worsens a patient's already compromised ability to resist other infections. The causative organism is Leishmania, a protozoal parasite transmitted to humans through sandfly bites. Seasonal climate changes, environmental degradation (through agriculture), mass movement of people (economic migration) and decreased immunity (through malnutrition) promote epidemic outbursts. Leishmaniasis infection presents in 3 forms: cutaneous, producing a large number of lesions on the face, arms and legs; mucocutaneous, causing disfiguring destruction of the mucous membranes of the nose, mouth and throat and surrounding tissues; or visceral, resulting in wasting, concurrent infections (mainly pneumonia and diarrheal disease) and bleeding secondary to thrombocytopenia and impaired liver function. In visceral leishmaniasis, the parasite infects macrophages throughout the reticuloendothelial system, compromising the immune system. Untreated, visceral leishmaniasis is uniformly fatal.

HIV/AIDS and leishmaniasis comprise a mutually reinforcing cycle of infection. Leishmaniasis accelerates the onset of AIDS by encouraging further opportunistic infections (e.g., pneumonia, tuberculosis), and thus it reduces the life expectancy of people with HIV infection. Meanwhile, HIV-related immunosuppression increases the risk of acquiring leishmaniasis by 100–1000 times in endemic areas and encourages the development of relapsing and eventually drug-resistant leishmaniasis. In a European study, 79%–90% of people with HIV–visceral leishmaniasis coinfection were found to have CD4 cell counts of less than 200 х 106/L;1 in Ethiopia, most patients die before reaching such low CD4 counts.

Diagnosis and treatment

In January 2004, Médecins Sans Frontières and the Tigray Bureau of Health initiated Ethiopia's first free HIV/AIDS treatment program. The high prevalence of visceral leishmaniasis in the area created a particularly challenging clinical reality: here, guidelines from the World Health Organization (WHO) on antiretroviral therapy in resource-limited settings need to be balanced with locally appropriate protocols for identifying and treating HIV and visceral leishmaniasis coinfection.

In the developing world, where limited health care resources make CD4 counts difficult to obtain, low total lymphocyte counts and the presence of WHO Clinical Stage III features have been successfully used as proxies for low CD4 cell counts and viral loads in determining HIV infection and the need for antiretroviral therapy. However, in Kafta Humera Woreda, we found that clinical features of HIV/AIDS were less helpful as a guide for initiating antiretroviral therapy because they closely resemble the clinical manifestations of leishmaniasis. Moreover, visceral leishmaniasis itself reduces CD4 counts; depressed total lymphocyte and CD4 counts among coinfected patients rebound after treatment of leishmaniasis. Therefore, in coinfected patients, total lymphocyte and CD4 counts are unreliable indications for antiretroviral therapy.

Identifying the organism L. donovani from a tissue aspirate is the “gold standard” diagnosis for visceral leishmaniasis; however, this test is impractical to perform in a setting where the disease is highly endemic. Instead, a serologic direct agglutination test (DAT) is used as the first-line diagnostic tool.

We rely on DAT titres and clinical assessment to diagnose visceral leishmaniasis in this resource-constrained setting with a high volume of patients (between 1500 and 2000 cases per year). High DAT titres (≥ 1:6400) confirm diagnosis, and low titres (≤ 1:400) rule it out. Aspiration is performed only when DAT titres are intermediate. We have thus reduced the need for aspirate diagnosis in about 90% of cases.

The first-line drug for treating visceral leishmaniasis is sodium stibogluconate (20 mg/ kg by intramuscular injection for 30 days). Despite poor tolerance of this treatment among patients coinfected with HIV and visceral leishmaniasis — one-third die during treatment because of drug-induced pancreatitis2 we use it in our program and, over the last 2 years, have seen a dramatic reduction in the rates of death caused by the disease and an increase in cure rates (Fig. 1). Other, less toxic drugs (e.g., liposomal amphotericin, miltefosine) have remained unavailable to the region.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint

Fig. 1: Visceral leishmaniasis cure and death rates, Kafta Humera Woreda, 1998–2004.

We attribute our success in increasing cure rates and reducing death rates to the development of an efficient strategy for screening and diagnosis that allows us to identify active cases among migrant farm workers in Kafta Humera Woreda and the decentralization of diagnostic and treatment services. These factors have also led to a rise in the treatment of primary cases of visceral leishmaniasis in Kafta Humera Woreda (Fig. 2). We hope that the results from this project will result in a national policy for the diagnosis and treatment of visceral leishmaniasis and HIV coinfection in resource-limited regions that will include less toxic drug therapies.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint

Fig. 2: Primary visceral leishmaniasis cases treated in Kafta Humera Woreda, 1997–2004.

  • Kala-azar, a term originating in Assam, India, means “black disease” and is another name for visceral leishmaniasis. It refers to the increased pigmentation on the face and trunk that accompanies the disease. The illness is characterized by intermittent fever, weight loss, splenomegaly, hepatomegaly and anemia.

References

  1. 1.↵
    Alvar J, Gutierrez-Solar B, Molina R, Lopez-Velez R, Garcia-Camacho A, Martinez P, et al. Prevalence of Leishmania infection among AIDS patients [letter]. Lancet 1992; 339: 1427.
    OpenUrlPubMed
  2. 2.↵
    Ritmeijer K, Veeken H, Melaku Y, Leal G, Amsalu R, Seaman J, et al. Ethiopian visceral leishmaniasis: generic and proprietary sodium stibogluconate are equivalent; HIV co-infected patients have a poor outcome. Trans R Soc Trop Med Hyg 2001; 95:668-72.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 172 (11)
CMAJ
Vol. 172, Issue 11
24 May 2005
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Treating HIV/AIDS and leishmaniasis coinfection in Ethiopia
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Treating HIV/AIDS and leishmaniasis coinfection in Ethiopia
Aranka Anema, Koert Ritmeijer
CMAJ May 2005, 172 (11) 1434-1435; DOI: 10.1503/cmaj.050511

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Treating HIV/AIDS and leishmaniasis coinfection in Ethiopia
Aranka Anema, Koert Ritmeijer
CMAJ May 2005, 172 (11) 1434-1435; DOI: 10.1503/cmaj.050511
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Diagnosis and treatment
    • References
  • Figures & Tables
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Visceral Leishmaniasis in Benishangul-Gumuz Regional State, Western Ethiopia: Reemerging or Emerging?
  • Importance of Nonenteric Protozoan Infections in Immunocompromised People
  • HIV/AIDS and leishmaniasis coinfection in Ethiopia
  • HIV/AIDS and leishmaniasis coinfection in Ethiopia
  • Google Scholar

More in this TOC Section

  • Applying the 2005 Canadian Hypertension Education Program recommendations: 4. Managing uncomplicated hypertension
  • A newborn requiring selective bronchial intubation
  • Does β-blocker prophylaxis improve survival after major noncardiac surgery?
Show more Synopsis

Similar Articles

Collections

  • Topics
    • Global health
    • HIV & AIDS

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: [email protected]

CMA Civility, Accessibility, Privacy

 

Powered by HighWire